Ally Therapeutics is a biotech company focused on enhancing the safety and efficacy of in vivo gene therapies by addressing immune response challenges through targeted modulation of the immune system. Their approach aims to improve patient outcomes by minimizing adverse reactions and maximizing therapeutic effectiveness in gene therapy applications.

Applied EV develops a modular vehicle system for autonomous transport, utilizing the Blanc Robot platform and its proprietary Digital Backbone™ to enable safety-rated, programmable Software Defined Vehicles. This technology addresses the need for decarbonized fleets and reduced operational costs by facilitating level 4 and 5 autonomy across various commercial applications.

The startup develops boron neutron capture therapy (BNCT) technology that precisely targets and delivers boron to cancer cells, effectively eliminating solid tumors while preserving healthy tissue. This approach enhances treatment efficacy for various cancers, improving patient outcomes through targeted therapy.

This company provides comprehensive veterinary services delivered directly to the pet owner's home environment. They focus on building trust and reducing pet anxiety by offering gentle, accessible medical care where the animal is most comfortable. BlueSky ensures continuity of care through transparent communication and personalized treatment plans for every patient.

Cor AI agents enable Customer Success teams to track and analyze customer signals from various sources, including conversations and internal data, to facilitate timely and personalized customer interactions. This technology addresses the challenge of generic engagements by automating the generation of tailored communications that enhance customer retention and drive growth.

CuraSen Therapeutics develops orphan drugs targeting neurodegenerative diseases by utilizing advanced pharmacological approaches to enhance neuroprotection and promote neuronal health. The company focuses on addressing the unmet medical needs of patients suffering from conditions like Alzheimer's and Parkinson's, where current treatment options are limited.

DEM BioPharma develops first-in-class cancer therapeutics focused on novel targets for solid tumors. The company advances a pipeline of proprietary drug candidates through preclinical and clinical development stages. Their work aims to introduce new treatment modalities for difficult-to-treat malignancies.

DispatchHealth provides on-demand medical care by dispatching healthcare professionals to patients' homes, equipped with the necessary tools to treat a wide range of health concerns. This service reduces the need for emergency room visits, offering a more convenient and cost-effective alternative for urgent medical needs.

Edgewood Oncology is a clinical‑stage biotech developing BTX‑A51, a small‑molecule multi‑kinase inhibitor that co‑targets CK1α, CDK7 and CDK9 to suppress MDM2 and MCL‑1 transcription, thereby restoring p53‑mediated apoptosis. The drug is being evaluated in Phase 2 trials for relapsed/refractory acute myeloid leukemia, high‑risk myelodysplastic syndrome, and genetically defined solid tumors such as GATA3‑mutant breast cancer, offering a safety profile that avoids the toxicities of direct MDM2 or MCL‑1 inhibitors.

The startup develops a gene editing and genome engineering platform that creates human-compatible organ tissue cells for solid organ and therapeutic cell transplantation. This technology aims to improve outcomes for patients with life-threatening diseases by enabling successful kidney and islet cell transplants.

EOT provides the Twin Fusion platform, which integrates operational technology (OT) and information technology (IT) to enable real-time monitoring and optimization of industrial assets through machine learning and data analytics. This solution addresses the challenge of operational complexity by delivering actionable insights that enhance efficiency and reduce costs across enterprise-wide systems.

Flex provides an AI-native financial platform integrating business banking, credit, expense management, and global payments for business owners. The platform automates accounts payable and receivable processes while offering flexible credit terms like Net-60. It aims to unify business and personal financial management into a single ecosystem for operational optimization.

Free Market Health offers a cloud-based marketplace platform that streamlines specialty pharmacy referrals and reimbursement processes, ensuring efficient medication delivery to patients. The platform provides real-time tracking of referrals and pharmacy performance, enabling payers and pharmacies to optimize costs and enhance patient outcomes.

Gen+ is a digital platform that provides leadership and meta-skills education for learners aged 9-14 and their teachers, utilizing a blended learning approach that combines online and in-person instruction. The program addresses the lack of standardized skills development in schools by equipping students with essential, transferable skills necessary for success in learning, work, and life.

Harbor Health operates a multi-specialty clinic group that utilizes telehealth technology to provide immediate access to healthcare services, including virtual express care for common conditions. Their co-creation approach to patient care enhances engagement and satisfaction, ensuring personalized treatment plans that address individual health needs.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

Kelonia develops genetic medicines utilizing its proprietary iGPS® technology for targeted delivery of genetic cargo to specific tissues. The company is advancing its pipeline, including in vivo BCMA CAR-T therapies for hematologic malignancies. This platform aims to efficiently provide genetic medicine solutions across a broad patient population.

Lassen Therapeutics develops fully human monoclonal antibodies targeting the interleukin-11 receptor to treat fibrotic diseases such as thyroid eye disease and idiopathic pulmonary fibrosis. Their approach aims to inhibit IL-11 signaling, addressing the underlying mechanisms of fibrosis to improve patient outcomes.

The startup has developed a proprietary platform that utilizes parallel, multiplexed, and unbiased systems to identify and therapeutically target antibody interactions responsible for immune diseases. This technology enables researchers to monitor human immune responses in conditions such as autoimmunity, severe allergies, oncology, and infectious diseases, facilitating the development of targeted therapeutics.

Lumena Pharmaceuticals develops oral therapeutics targeting rare liver diseases, utilizing advanced biomedical design to enhance liver function and alleviate disease symptoms. Their approach addresses the unmet medical needs in liver health by providing effective treatment options that improve patient outcomes.

The startup develops anti-tumor monoclonal human recombinant antibodies that utilize antibody-drug conjugates to specifically target cancer cells and deliver cytotoxic agents directly into them. This approach enhances the precision of cancer treatment, minimizing damage to healthy tissues while maximizing therapeutic efficacy.

Ola is a finance super app designed specifically for US Hispanics and Latinxs, providing tools for investment, savings, and financial planning. By addressing the significant gap in stock and cryptocurrency ownership among Latinx individuals, Ola empowers users to create personalized financial strategies and access high-yield investment accounts.

Oven develops Bun, a fast all-in-one JavaScript runtime, bundler, and package manager that streamlines the development process for web applications. By integrating these essential tools, Bun reduces setup time and enhances performance, allowing developers to focus on building features rather than managing configurations.

PatientsLikeMe is an online platform where individuals with chronic or rare conditions record symptoms, medications, side effects, and functional status in a structured health journal and view personalized trend dashboards. The aggregated, anonymized patient‑reported data generate treatment effectiveness scores and can be securely exported via CSV or HL7 FHIR API for clinicians and researchers, while condition‑specific communities facilitate peer support and information exchange.